Bacil Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2020 - 2016
Selling, General & Admin	0.78	1.38	0.99	0.86	0.6	0.52	Upgrade
Other Operating Expenses	1.63	1.14	0.88	0.91	0.95	1.09	Upgrade
Operating Expenses	2.41	2.53	1.89	1.8	1.59	1.67	Upgrade
Operating Income	-2.41	-2.53	-1.89	-1.8	-1.59	-1.67	Upgrade
Interest Expense	-0.01	-0.01	-0.01	-0.01	-0.01	-0.05	Upgrade
Interest & Investment Income	0.83	0.83	0.3	0.29	0.58	0.74	Upgrade
Other Non Operating Income (Expenses)	5.88	0.4	-	-	-	-	Upgrade
EBT Excluding Unusual Items	4.29	-1.31	-1.6	-1.52	-1.02	-0.97	Upgrade
Gain (Loss) on Sale of Investments	5.38	5.38	1.01	0.5	-0.63	-1.42	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	-	-36.95	-	Upgrade
Pretax Income	9.67	4.08	-0.59	-1.02	-38.6	-2.4	Upgrade
Income Tax Expense	2.3	0.03	0	-0	-0	-0	Upgrade
Net Income	7.38	4.04	-0.59	-1.02	-38.6	-2.39	Upgrade
Net Income to Common	7.38	4.04	-0.59	-1.02	-38.6	-2.39	Upgrade
Shares Outstanding (Basic)	12	6	6	6	6	6	Upgrade
Shares Outstanding (Diluted)	12	6	6	6	6	6	Upgrade
Shares Change (YoY)	116.22%	6.92%	-1.47%	1.71%	0.99%	-0.04%	Upgrade
EPS (Basic)	0.60	0.64	-0.10	-0.17	-6.55	-0.41	Upgrade
EPS (Diluted)	0.60	0.64	-0.10	-0.17	-6.55	-0.41	Upgrade
Free Cash Flow	-	4.01	-0.03	-1.48	-40.09	-3.98	Upgrade
Free Cash Flow Per Share	-	0.64	-0.01	-0.25	-6.80	-0.68	Upgrade
EBITDA	-2.42	-2.53	-1.87	-1.77	-1.55	-1.62	Upgrade
D&A For EBITDA	-0	0.01	0.02	0.03	0.04	0.05	Upgrade
EBIT	-2.41	-2.53	-1.89	-1.8	-1.59	-1.67	Upgrade
Effective Tax Rate	23.73%	0.85%	-	-	-	-	Upgrade
Revenue as Reported	12.09	6.61	1.31	1.15	0.58	0.74	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.